MNPR
Monopar Therapeutics Inc.NASDAQHealthcare$55.13-2.63%ClosedMarket Cap: $368.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
4016.19
DCF Value
$8,322.24
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.0%
ROA
-0.0%
ROIC
-0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-6.2M | $-5.2M | $-0.78 | — |
| FY 2025 | $0.00 | NaN% | $-16.7M | $-13.7M | $-1.85 | — |
| Q3 2025 | $0.00 | NaN% | $-4.1M | $-3.4M | $-0.48 | — |
| Q2 2025 | $0.00 | NaN% | $-3.2M | $-2.5M | $-0.35 | — |
| Q1 2025 | $0.00 | NaN% | $-3.2M | $-2.6M | $-0.38 | — |
| Q4 2024 | $0.00 | NaN% | $-11.1M | $-10.9M | $-0.95 | — |
| FY 2024 | $0.00 | NaN% | $-16.2M | $-15.6M | $-1.36 | — |
| Q3 2024 | $0.00 | NaN% | $-1.6M | $-1.3M | $-0.11 | — |
| Q2 2024 | $0.00 | NaN% | $-1.8M | $-1.7M | $-0.15 | — |
| Q1 2024 | $0.00 | NaN% | $-1.7M | $-1.6M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-1.9M | $-1.8M | $-0.12 | — |
| FY 2023 | $0.00 | NaN% | $-8.8M | $-8.4M | $-0.58 | — |